<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Crit Care</journal-id><journal-id journal-id-type="iso-abbrev">Crit Care</journal-id><journal-title-group><journal-title>Critical Care</journal-title></journal-title-group><issn pub-type="ppub">1364-8535</issn><issn pub-type="epub">1466-609X</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4098503</article-id><article-id pub-id-type="publisher-id">cc3416</article-id><article-id pub-id-type="doi">10.1186/cc3416</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Prophylaxis of contrast-induced nephropathy in patients with impaired renal function: double-blind comparison of acetylcysteine, theophylline, acetylcysteine + theophylline and placebo</article-title></title-group><contrib-group><contrib contrib-type="author" id="A1"><name><surname>Huber</surname><given-names>W</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Schilling</surname><given-names>C</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Wacker</surname><given-names>A</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Hennig</surname><given-names>M</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Greiner</surname><given-names>L</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Rutz</surname><given-names>T</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Umgelter</surname><given-names>A</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Eckel</surname><given-names>F</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A9"><name><surname>Vogelsang</surname><given-names>B</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A10"><name><surname>Schoemig</surname><given-names>A</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A11"><name><surname>Heemann</surname><given-names>U</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A12"><name><surname>Schmid</surname><given-names>R</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib></contrib-group><aff id="I1"><label>1</label>Second Medical Department, Klinikum Rechts der Isar, Munich, Germany</aff><aff id="I2"><label>2</label>1st Medical Department, Munich, Germany</aff><aff id="I3"><label>3</label>Institute for Medical Statistics and Epidemiology, Munich, Germany</aff><pub-date pub-type="ppub"><year>2005</year></pub-date><pub-date pub-type="epub"><day>7</day><month>3</month><year>2005</year></pub-date><volume>9</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">25th International Symposium on Intensive Care and Emergency Medicine</named-content></supplement><fpage>P353</fpage><lpage>P353</lpage><permissions><copyright-statement>Copyright &#x000a9; 2005 BioMed Central Ltd</copyright-statement><copyright-year>2005</copyright-year><copyright-holder>BioMed Central Ltd</copyright-holder></permissions><conference><conf-date>21-25 March 2005</conf-date><conf-name>25th International Symposium on Intensive Care and Emergency Medicine</conf-name><conf-loc>Brussels, Belgium</conf-loc></conference></article-meta></front><body><sec><title>Background</title><p>Contrast-induced nephropathy (CIN) is frequently found in ICU patients. Several recent studies have shown a prophylactic effect of acetylcysteine (A) and theophylline (T). The results are contradictory, however, and only one study has so far compared the effects of both agents [<xref ref-type="bibr" rid="B1">1</xref>]. Nevertheless, this study did not include a placebo group and was not restricted to patients with impaired renal function.</p></sec><sec><title>Aim</title><p>To compare the effects of A, T, a combination of A and T (A + T) and placebo (P) in patients with impaired renal function.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><p>Two hundred and fifty-four patients with serum creatinine &#x02265; 1.3 mg/dl receiving &#x02265; 100 ml contrast-medium (CM) were randomised to receive A (600 mg, p.o., b.i.d.; start 24 hours before CM), T (200 mg, i.v., 30 min before CM), A + T, or P. <italic>Primary endpoint </italic>The incidence of CIN (increase of serum creatinine &#x02265; 0.5 mg/dl within 48 hours). <italic>Secondary endpoint </italic>Time course of serum-creatinine. <italic>Statistics </italic>Chi-square-test and Wilcoxon-test, SAS software version 6.12.</p></sec><sec sec-type="results"><title>Results</title><p>Patients of groups A, T, A + T and P were comparable with regard to baseline creatinine (1.49 &#x000b1; 0.43 vs 1.53 &#x000b1; 0.56 vs 1.57 &#x000b1; 0.40 vs 1.69 &#x000b1; 0.77 mg/dl; not significant [NS]), amount of CM (192.5 &#x000b1; 104.3 vs 240.2 &#x000b1; 149.9 vs 222.7 &#x000b1; 141.9 vs 207.6 &#x000b1; 113.6 ml; NS) and incidence of other risk factors (RF) such as diabetes and hypertension. The incidence of CIN was 4/62 (6.5%) in group A, 3/64 (4.7%) in group T, 7/66 (10.6%) in group A + T, and 10/62 (16.1%) in group P. Overall, the incidence was lower under prophylaxis (14/192; 7.3%) than under placebo (10/62, 16.1%; <italic>P </italic>= 0.0386). Patients of group T had a significantly lower incidence of CIN than patients under placebo (<italic>P </italic>= 0.0348), whereas neither group A nor group A + T had a lower incidence of CIN than group P.</p><p>Compared with baseline, serum creatinine levels significantly increased after 48 hours in group A (1.54 &#x000b1; 0.39 vs 1.49 &#x000b1; 0.43 mg/dl; <italic>P </italic>= 0.00986), group A + T (1.63 &#x000b1; 0.41 vs 1.57 &#x000b1; 0.40 mg/dl; <italic>P </italic>= 0.0075) and group P (1.80 &#x000b1; 0.85 vs 1.69 &#x000b1; 0.77 mg/dl; <italic>P </italic>= 0.00619). However, there was no significant increase in group T (1.56 &#x000b1; 0.55 vs 1.53 &#x000b1; 0.56 mg/dl; NS).</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>In patients with impaired renal function theophylline significantly reduces the incidence of CIN, whereas acetylcysteine alone or in combination with theophylline was not effective.</p></sec></body><back><ref-list><ref id="B1"><mixed-citation publication-type="other"><source>Intensive Care Med</source><year>2002</year><volume>9</volume><issue>Suppl 1</issue><fpage>S139</fpage><pub-id pub-id-type="doi">10.1007/s00134-001-1194-1</pub-id></mixed-citation></ref></ref-list></back></article>